A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

Abroad (travel likely)RecruitingPHASE1

Conditions

Multiple Myeloma · Hematologic Malignancies

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

West China Hospital of Sichuan University, Chengdu, Sichuan, China
Contact: Study coordinator (Ting Niu)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Birmingham, United States · Phoenix, United States

A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma (MM)

Abroad (travel likely)RecruitingPHASE1

Springdale, United States · Jacksonville, United States

Hypofractionation (Radiation) Trial for Multiple Myeloma

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Chicago, United States

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

St Louis, United States